Aptevo Therapeutics (APVO) Debt to Equity (2016 - 2022)
Historic Debt to Equity for Aptevo Therapeutics (APVO) over the last 8 years, with Q4 2022 value amounting to $0.19.
- Aptevo Therapeutics' Debt to Equity fell 9847.92% to $0.19 in Q4 2022 from the same period last year, while for Dec 2022 it was $0.19, marking a year-over-year decrease of 9847.92%. This contributed to the annual value of $0.19 for FY2022, which is 9847.92% down from last year.
- Latest data reveals that Aptevo Therapeutics reported Debt to Equity of $0.19 as of Q4 2022, which was down 9847.92% from $0.25 recorded in Q3 2022.
- Aptevo Therapeutics' Debt to Equity's 5-year high stood at $12.64 during Q4 2021, with a 5-year trough of -$0.82 in Q1 2022.
- For the 5-year period, Aptevo Therapeutics' Debt to Equity averaged around $1.98, with its median value being $0.69 (2019).
- In the last 5 years, Aptevo Therapeutics' Debt to Equity surged by 104657.54% in 2020 and then crashed by 15802.05% in 2022.
- Aptevo Therapeutics' Debt to Equity (Quarter) stood at $0.63 in 2018, then skyrocketed by 164.56% to $1.68 in 2019, then fell by 9.99% to $1.51 in 2020, then skyrocketed by 737.39% to $12.64 in 2021, then plummeted by 98.48% to $0.19 in 2022.
- Its last three reported values are $0.19 in Q4 2022, $0.25 for Q3 2022, and $0.19 during Q2 2022.